ArticleBMC urology2025
Renal cancer survival and use of 5alpha-reductase inhibitors or androgen deprivation therapy.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of long-term 5α-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSeveral etiological factors have been implicated in renal cell carcinoma (RCC), and hormonal receptor activity appears to influence RCC-specific mortality. This study aimed to examine the potential association between the use of 5α-reductase inhibitors and androgen deprivation therapy (ADT) and RCC-specific mortality in a population-based cohort of men.
methodsThis study included a cohort of 7,720 Finnish men newly diagnosed with RCC between 1995 and 2012. The median follow-up period was 4.75 years. The risk of RCC-specific mortality associated with the use of 5α-reductase inhibitors and androgen deprivation therapy was analyzed using Cox proportional hazards regression. The influence of tumor histology and primary treatment were also evaluated. Long-term risks were assessed in lag-time analyses. Potential confounding by indication was addressed by repeating the analyses for α-blocker users for comparison.
resultsUse of 5α-reductase inhibitors prior to RCC diagnosis was associated with a slight risk increase for RCC-specific mortality compared to non-users (HR 1.18, 95% CI 1.02-1.36), with similar association observed also among α-blocker users. However, post-diagnostic use of 5α-reductase inhibitors was not associated with RCC-specific mortality (HR 0.93, 95% CI 0.81-1.07). The lag time analysis did not demonstrate any long-term risk reduction for either 5α-reductase inhibitors or α-blockers. Additionally, no association was observed between ADT use and RCC-specific mortality.
conclusionUse of 5α-reductase inhibitors or androgen deprivation therapy does not consistently associate with RCC-survival following diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.